BioCentury | Feb 23, 2018
Emerging Company Profile

Cutting viruses

...to Editas. At least three companies are evaluating shock and kill strategies in the clinic. Aphios Corp....
...editing to target viral genomes Companies and Institutions Mentioned Agenovir Corp., South San Francisco, Calif. Aphios Corp....
BioCentury | Feb 2, 2017
Strategy

Cure cash

...science and data, and what other things are not working so well.” Romas Geleziunas, Gilead Aphios Corp....
...alone and in combination with an HDAC inhibitor for HIV. CEO Trevor Castor told BioCentury Aphios...
...will likely have a greater effect.” Companies and Institutions Mentioned Aarhus University Hospital, Aarhus, Denmark Aphios Corp....
BioCentury | Dec 3, 2015
Distillery Therapeutics

Therapeutics: K-Ras (KRAS); calmodulin; protein kinase C (PKC)

...with vehicle. Next steps could include testing other PKC activators in models of pancreatic cancer. Aphios Corp....
BioCentury | Mar 12, 2015
Distillery Therapeutics

Therapeutics: Protein kinase C (PKC) α (PRKCA); PKC δ (PRKCD); PKC θ (PRKCQ)

...and has the gel in Phase II testing to treat basal cell carcinoma and cancer. Aphios Corp....
BioCentury | Nov 25, 2013
Company News

Aphios neurology, ophthalmic news

...Amylon is raising debt and equity capital from high net worth individuals and institutional investors. Aphios'...
...ginger product, is in Phase III testing to treat chemotherapy induced nausea and vomiting (CINV). Aphios Corp....
BioCentury | Jun 17, 2013
Company News

Aphios, VivaCell deal

...to treat MS and Huntington's disease (HD). The companies could not be reached for details. Aphios Corp....
BioCentury | Mar 23, 2009
Company News

Aphios, Louisiana State University deal

...the university's IP covering pharmaceutical compositions of bryostatin-1, a modulator of protein kinase C activity. Aphios...
...for Alzheimer's disease. The university will receive fees and is eligible for milestones and royalties. Aphios Corp....
BioCentury | Sep 24, 2007
Company News

Aphios, Boston University Medical Center, NIH cancer news

...grant from NIH's National Cancer Institute to develop APH-M109 to treat hormone-refractory prostate cancer (HRPC). Aphios...
...D analog by 2010. The university granted Aphios exclusive, worldwide rights to APH-M109 in 2005. Aphios Corp....
BioCentury | Jan 23, 2006
Company News

Aphios infectious news

...Cancer and infectious disease company Aphios formed Amyxa Pharmaceuticals, a subsidiary that will focus on discovering...
...identify the compounds by screening marine microorganisms and medicinal plants using SuperFluids CXF fractionation technology. Aphios Corp....
BioCentury | Dec 19, 2005
Company News

Aphios, Boston University Medical School deal

...analog that is in preclinical development to treat prostate cancer. Further terms were not disclosed. Aphios Corp....
Items per page:
1 - 10 of 26
BioCentury | Feb 23, 2018
Emerging Company Profile

Cutting viruses

...to Editas. At least three companies are evaluating shock and kill strategies in the clinic. Aphios Corp....
...editing to target viral genomes Companies and Institutions Mentioned Agenovir Corp., South San Francisco, Calif. Aphios Corp....
BioCentury | Feb 2, 2017
Strategy

Cure cash

...science and data, and what other things are not working so well.” Romas Geleziunas, Gilead Aphios Corp....
...alone and in combination with an HDAC inhibitor for HIV. CEO Trevor Castor told BioCentury Aphios...
...will likely have a greater effect.” Companies and Institutions Mentioned Aarhus University Hospital, Aarhus, Denmark Aphios Corp....
BioCentury | Dec 3, 2015
Distillery Therapeutics

Therapeutics: K-Ras (KRAS); calmodulin; protein kinase C (PKC)

...with vehicle. Next steps could include testing other PKC activators in models of pancreatic cancer. Aphios Corp....
BioCentury | Mar 12, 2015
Distillery Therapeutics

Therapeutics: Protein kinase C (PKC) α (PRKCA); PKC δ (PRKCD); PKC θ (PRKCQ)

...and has the gel in Phase II testing to treat basal cell carcinoma and cancer. Aphios Corp....
BioCentury | Nov 25, 2013
Company News

Aphios neurology, ophthalmic news

...Amylon is raising debt and equity capital from high net worth individuals and institutional investors. Aphios'...
...ginger product, is in Phase III testing to treat chemotherapy induced nausea and vomiting (CINV). Aphios Corp....
BioCentury | Jun 17, 2013
Company News

Aphios, VivaCell deal

...to treat MS and Huntington's disease (HD). The companies could not be reached for details. Aphios Corp....
BioCentury | Mar 23, 2009
Company News

Aphios, Louisiana State University deal

...the university's IP covering pharmaceutical compositions of bryostatin-1, a modulator of protein kinase C activity. Aphios...
...for Alzheimer's disease. The university will receive fees and is eligible for milestones and royalties. Aphios Corp....
BioCentury | Sep 24, 2007
Company News

Aphios, Boston University Medical Center, NIH cancer news

...grant from NIH's National Cancer Institute to develop APH-M109 to treat hormone-refractory prostate cancer (HRPC). Aphios...
...D analog by 2010. The university granted Aphios exclusive, worldwide rights to APH-M109 in 2005. Aphios Corp....
BioCentury | Jan 23, 2006
Company News

Aphios infectious news

...Cancer and infectious disease company Aphios formed Amyxa Pharmaceuticals, a subsidiary that will focus on discovering...
...identify the compounds by screening marine microorganisms and medicinal plants using SuperFluids CXF fractionation technology. Aphios Corp....
BioCentury | Dec 19, 2005
Company News

Aphios, Boston University Medical School deal

...analog that is in preclinical development to treat prostate cancer. Further terms were not disclosed. Aphios Corp....
Items per page:
1 - 10 of 26